NV

Novocure LtdNASDAQ NVCR Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

1.778

Small

Exchange

XNAS - Nasdaq

NVCR Stock Analysis

NV

Uncovered

Novocure Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-33/100

Low score

Market cap $B

1.778

Dividend yield

Shares outstanding

105.45 B

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. The company is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company’s key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The firm markets Optune in the United States, Germany, Japan and other countries. The firm markets Optune Lua in the United States and European Union. The company also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.

View Section: Eyestock Rating